BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 17868855)

  • 1. Chronic eosinophilic leukemias and the myeloproliferative variant of the hypereosinophilic syndrome.
    Bain BJ; Fletcher SH
    Immunol Allergy Clin North Am; 2007 Aug; 27(3):377-88. PubMed ID: 17868855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia.
    Cools J; Stover EH; Wlodarska I; Marynen P; Gilliland DG
    Curr Opin Hematol; 2004 Jan; 11(1):51-7. PubMed ID: 14676627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unique association of myeloid neoplasm with eosinophilia and abnormalities of PDGFRA with TTP.
    Chaudhary LN; Bailey NG; Vos JA; Stotler CJ
    W V Med J; 2013; 109(2):6-9. PubMed ID: 23600098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib Treatment of Lymphomatoid Papulosis Associated with Myeloproliferative Hypereosinophilic Syndrome Presenting the FIP1L1-PDGFRA Fusion Gene.
    García-Martínez P; Sitjas D; Llistosella E; Espinet B; Rodríguez-Rivera M; Hernandez-Muñoz M; Gallardo F; Pujol RM
    Acta Derm Venereol; 2017 Jul; 97(7):855-857. PubMed ID: 28374041
    [No Abstract]   [Full Text] [Related]  

  • 5. Myeloid neoplasms with eosinophilia.
    Reiter A; Gotlib J
    Blood; 2017 Feb; 129(6):704-714. PubMed ID: 28028030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic myeloproliferative disorders: the role of tyrosine kinases in pathogenesis, diagnosis and therapy.
    Macdonald D; Cross NC
    Pathobiology; 2007; 74(2):81-8. PubMed ID: 17587879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypereosinophilic syndrome: lymphoproliferative and myeloproliferative variants.
    Roufosse F; Goldman M; Cogan E
    Semin Respir Crit Care Med; 2006 Apr; 27(2):158-70. PubMed ID: 16612767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias.
    Vandenberghe P; Wlodarska I; Michaux L; Zachée P; Boogaerts M; Vanstraelen D; Herregods MC; Van Hoof A; Selleslag D; Roufosse F; Maerevoet M; Verhoef G; Cools J; Gilliland DG; Hagemeijer A; Marynen P
    Leukemia; 2004 Apr; 18(4):734-42. PubMed ID: 14973504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular classification and pathogenesis of eosinophilic disorders: 2005 update.
    Gotlib J
    Acta Haematol; 2005; 114(1):7-25. PubMed ID: 15995322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis.
    Bain BJ
    Am J Hematol; 2004 Sep; 77(1):82-5. PubMed ID: 15307112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cough and hypereosinophilia due to FIP1L1-PDGFRA fusion gene with tyrosine kinase activity.
    Chung KF; Hew M; Score J; Jones AV; Reiter A; Cross NC; Bain BJ
    Eur Respir J; 2006 Jan; 27(1):230-2. PubMed ID: 16387954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases.
    La Starza R; Specchia G; Cuneo A; Beacci D; Nozzoli C; Luciano L; Aventin A; Sambani C; Testoni N; Foppoli M; Invernizzi R; Marynen P; Martelli MF; Mecucci C
    Haematologica; 2005 May; 90(5):596-601. PubMed ID: 15921374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic eosinophilic leukaemia revealed by lymphomatoid papulosis: the role of the FIP1-like 1-platelet-derived growth factor receptor alpha fusion gene.
    Thuny C; Gaudy-Marqueste C; Nicol I; Gabert J; Costello R; Grob JJ; Richard MA
    J Eur Acad Dermatol Venereol; 2010 Feb; 24(2):234-5. PubMed ID: 19686260
    [No Abstract]   [Full Text] [Related]  

  • 14. Management of F/P+/- hypereosinophilic syndromes: case report and treatment review.
    Kalra A; Palaniswamy C; Kalra A; Wig N; Sood R
    Am J Ther; 2012 Sep; 19(5):e146-51. PubMed ID: 20724910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [FIP1L1-PDGFRalpha-positive myeloproliferative disease with hypereosinophilia: clinical characteristics and pathogenetic therapy].
    Nemchenko IS; Khoroshko ND; Turkina AG; Sokolova MA; Kokhno AV; Semenova EA; Zakharova AV
    Ter Arkh; 2005; 77(7):90-2. PubMed ID: 16116920
    [No Abstract]   [Full Text] [Related]  

  • 16. Severe Prolonged Cough as Presenting Manifestation of FIP1L1-PDGFRA+ Chronic Eosinophilic Leukaemia: A Widely Ignored Association.
    Roufosse F; Heimann P; Lambert F; Sidon P; Bron D; Cottin V; Cordier JF
    Respiration; 2016; 91(5):374-9. PubMed ID: 27164940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FIP1L1-PDGFRA positive chronic eosinophilic leukaemia and associated central nervous system involvement.
    Williams C; Kalra S; Nath U; Bown N; Wilson V; Wilkins BS; Neylon AJ
    J Clin Pathol; 2008 May; 61(5):677-80. PubMed ID: 18256119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib.
    Wang LN; Pan Q; Fu JF; Shi JY; Jin J; Li JM; Hu J; Zhao WL; Chen Z; Chen SJ
    Chin Med J (Engl); 2008 May; 121(10):867-73. PubMed ID: 18706197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FIP1L1-PDGFRA positive chronic eosinophilic leukemia in Tunisian patients.
    Menif S; Omri H; Hafsia R; Ben Romdhane N; Turki S; Meddeb B; Dellagi K
    Pathol Biol (Paris); 2007 Jun; 55(5):242-5. PubMed ID: 17137731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management.
    Shomali W; Gotlib J
    Am J Hematol; 2019 Oct; 94(10):1149-1167. PubMed ID: 31423623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.